Therapeutic Efficacy of Artemether-Lumefantrine in Treating Un-complicated Plasmodium falciparum Malaria in Children at Wad-Medani, Sudan

Malaria remains a significant public health concern in Sudan, particularly among children, with Plasmodium falciparum as the dominant species. Artemether-Lumefantrine (AL) is the recommended first-line treatment for uncomplicated malaria; however, rising treatment failure rates necessitate further evaluation. This study assessed the therapeutic efficacy of AL in children aged 6 months to 16 years at Wad-Medani Pediatric Teaching Hospital, Gezira State. A prospective single-arm interventional study was conducted, enrolling 80 patients and following 70 through a 28-day treatment regimen. Clinical assessments, parasitological responses, and adherence evaluations were performed. The results showed a cure rate of 91.5%, with significant adherence-related outcomes (p<0.05). Early treatment failure (ETF) was observed in 5% of cases, with no late clinical or parasitological failures reported. Clinical pharmacist interventions improved awareness and adherence among healthcare providers and caregivers. The study concluded that AL remains highly effective for treating uncomplicated malaria in Sudan, although targeted interventions to enhance adherence are critical for sustained efficacy.